**APPENDIX**

The 2021 EULAR and ACR points to consider for diagnosis, management and monitoring of the IL 1 mediated autoinflammatory diseases: CAPS, TRAPS, MKD and DIRA

**CONTENTS**

## I. SUPPLEMENTARY METHODS

### I.1. Task force meetings proceedings:

Per EULAR[1] and ACR Standard Operating Procedures (SOPs) the following steps were followed.

- A EULAR task force was established and consisted of: 22 pediatric rheumatologists, 1 health care professional, 3 fellows, 2 patient representatives (one for each disease) from the autoinflammatory alliance, 1 methodologist and 1 senior methodologist.
- August 2019 (NIH Bethesda): A face-to-face meeting was convened to define the focus of the task force and identify the target population.
- Two rounds of pre-consensus meeting Delphi questionnaires were sent using RedCap, a secure Web-based system with the technical help of the University of Toronto. For one-week, daily reminders were sent to all task force members who had not yet replied to the questionnaire, and the response rate for each questionnaire was 100%. The same procedure was followed for the second Delphi survey. The questionnaire data and the results from the SLR were used to generate draft statements that were discussed in two consensus meetings.
- Due to the COVID-19 pandemic restrictions that prohibited face-to-face meetings, three consensus meetings were held virtually online. One consensus meeting included voting members with expertise in CAPS on October 27, 2020 one in TRAPS on November 24, 2020 and one in MKD and DIRA on November 4, 2020.
    - The SLR results were presented by the fellows for each disease and discussed during the consensus meetings.
    - The draft statements that were distributed to the task force members were discussed, refined and voted on.
    - Overarching statements and statements pertaining to all groups were voted on in all consensus meetings while statements pertaining to only CAPS, TRAPS or MKD and DIRA were voted on in the respective meetings only.
    - Statements with 20-80% agreement were chosen for ongoing discussion and possible major revision during the second part of the consensus meeting, while the rest (<20% agreement) were dropped and were not included as points to consider statements. Two conveners, 1 health care professional and 3 experts attended both meetings, and the rest of the expert panel attended one meeting based on their disease specific experience/expertise.
- Reaching consensus: All statements included reached the minimum 80% consensus to be retained in the final formulation of the recommendations. If one of the sub-statements did not reach that threshold in the pre-consensus Delphi or at the consensus meetings, it was discussed and reworded or modified with the aim of achieving a secondary 80% consensus. If the 80% level was not achieved in any way, the statement was eliminated. Eliminated statements were listed in the Supplementary II.5 below.
- A post-consensus meeting Delphi questionnaire with the finalized statements was distributed among all voting members of both consensus meetings and a level of agreement was obtained based on marking on a Likert scale from 0 to 10, with 0 indicating no agreement and 10 indicating full agreement. Using those data, the mean and standard deviation (SD) of level of agreement for each statement was calculated.

The manuscript was reviewed and approved by all task force members and the EULAR executive committee before submission.

## I.2. Search Terms

**a)** *Search Terms for* ***CAPS***

"cryopyrin associated periodic syndromes"[MeSH] OR "Cryopyrin Associated Periodic Syndromes"[tiab] OR "Cryopyrin Associated Periodic Syndrome"[tiab] OR "Cryopyrin Associated Periodic Fever Syndromes"[tiab] OR "Cryopyrin Associated Periodic Fever Syndrome"[tiab] OR cryopyrinopath*[tiab] OR FCAS[tiab] OR "Familial Cold Autoinflammatory Syndrome"[tiab] OR "Familial Cold Urticaria"[tiab] OR MWS[tiab] OR "Muckle Wells Syndrome"[tiab] OR CINCA[tiab] OR (Chronic[tiab] AND Infantile[tiab] AND Neurological[tiab] AND Cutaneous[tiab] AND Articular[tiab]) OR NOMID[tiab] OR "Neonatal Onset Multisystem Inflammatory Disease"[tiab] OR "Infantile Onset Multisystem Inflammatory Disease"[tiab]

**b)** ***Search Terms for TRAPS***

"Periodic fever, familial, autosomal dominant"[Supplementary Concept] OR "familial Hibernian fever"[tiab] OR ((((("tumor necrosis factor"[tiab] OR "tumour necrosis factor"[tiab] OR TNF[tiab]) AND receptor[tiab]) OR TNFR[tiab] OR TNFR1[tiab]) AND associated[tiab] AND periodic[tiab] AND syndrome[tiab])

c) ***Search Terms for MKD***
"mevalonate kinase deficiency"[MeSH] OR MKD[tiab] OR "mevalonate kinase deficiency""[tiab] OR "mevalonicaciduria"[tiab] OR HIDS[tiab] OR HyperIgD[tiab] OR "hyperimmunoglobulin D"[tiab] OR "hyperimmunoglobulinemia D"[tiab] OR "hyperimmunoglobulinaemia D"[tiab] OR (Hyper[tiab] AND (IgD[tiab] OR "Ig D"[tiab] OR "immunoglobulin D"[tiab]))

d) ***Search Terms for DIRA***

((((((((((((("Interleukin 1 Receptor Antagonist Protein/deficiency"[Mesh]) OR IL-1 receptor antagonist deficiency[TIAB]) OR DIRA[TIAB]) OR Deficiency of interleukin-1 receptor antagonist[Supplementary Concept])))) OR Deficiency of interleukin-1 receptor antagonist[TIAB])) OR ((((Hereditary Autoinflammatory Diseases[MH]) AND Interleukin 1 Receptor Antagonist Protein[MH])) AND ((interleukin-1 receptor antagonist[TIAB] OR IL1RN[TIAB] OR DIRA[TIAB])))))) OR ((IL1RN[TIAB]) AND deficien*[TIAB]))) OR ((((Interleukin 1 Receptor Antagonist Protein[MAJR]) AND Hereditary Autoinflammatory Diseases[MAJR])) AND deficien*[TIAB]))) OR (("IL-1 receptor antagonist"[Text Word]) AND ((Interleukin 1 Receptor Antagonist Protein[MAJR]) AND Hereditary Autoinflammatory Diseases[MAJR]))

## I.3. Flowcharts

**a.** *Flowchart for **CAPS***



**b)** *Flowchart for* ***TRAPS***



**c)** *Flowchart for* ***MKD***



**d)** *Flowchart for* ***DIRA***



## II. SUPPLEMENTARY MATERIALS

**II.1.** Included Articles for **CAPS**


1.Ahmadi N, Brewer CC, Zalewski C, King KA, Butman JA, Plass N, et al. Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations. Otolaryngol Head Neck Surg. 2011;145(2):295-302.
2.Al-Mayouf SM, Almutairi A, Albrawi S, Fathalla BM, Alzyoud R, AlEnazi A, et al. Pattern and diagnostic evaluation of systemic autoinflammatory diseases other than familial Mediterranean fever among Arab children: a multicenter study from the Pediatric Rheumatology Arab Group (PRAG). Rheumatol Int. 2020;40(1):49-56.
3.Awad F, Assrawi E, Jumeau C, Odent S, Despert V, Cam G, et al. The NLRP3 p.A441V Mutation in NLRP3-AID Pathogenesis: Functional Consequences, Phenotype-Genotype Correlations and Evidence for a Recurrent Mutational Event. ACR Open Rheumatol. 2019;1(4):267-76.
4.Brogan PA, Hofer M, Kuemmerle-Deschner JB, Kone-Paut I, Roesler J, Kallinich T, et al. Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger. Arthritis Rheumatol. 2019;71(11):1955-63.
5.Bujan-Rivas S, Basagana M, Sena F, Mendez M, Dordal MT, Gonzalez-Roca E, et al. Novel evidences of atypical manifestations in cryopyrin-associated periodic syndromes. Clinical and Experimental Rheumatology. 2017;35(Supplement108):S27-S31.
6.Caorsi R, Lepore L, Zulian F, Alessio M, Stabile A, Insalaco A, et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther. 2013;15(1):R33.
7.Caroli F, Pontillo A, D'Osualdo A, Travan L, Ceccherini I, Crovella S, et al. Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology. 2007;46(3):473-8.
8.Chuamanochan M, Weller K, Feist E, Kallinich T, Maurer M, Kummerle-Deschner J, et al. State of care for patients with systemic autoinflammatory diseases - Results of a tertiary care survey. World Allergy Organization Journal. 2019;12(3).
9.Cuisset L, Jeru I, Dumont B, Fabre A, Cochet E, Le Bozec J, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: Epidemiological study and lessons from eight years of genetic analysis in France. Annals of the Rheumatic Diseases. 2011;70(3):495-9.
10.Dode C, Le Du N, Cuisset L, Letourneur F, Berthelot JM, Vaudour G, et al. New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: A novel mutation underlies both syndromes. American Journal of Human Genetics. 2002;70(6):1498-506.
11.Dollfus H, Hafner R, Hofmann HM, Russo RA, Denda L, Gonzales LD, et al. Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood. Arch Ophthalmol. 2000;118(10):1386-92.
12.Elmi AA, Wynne K, Cheng IL, Eleftheriou D, Lachmann HJ, Hawkins PN, et al. Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome. Pediatric Rheumatology. 2019;17(1).

13.Eroglu FK, Kasapcopur O, Besbas N, Ozaltin F, Bilginer Y, Barut K, et al. Genetic and clinical features of cryopyrin-associated periodic syndromes in Turkish children. Clin Exp Rheumatol. 2016;34(6 Suppl 102):S115-s20.
14.Fingerhutova S, Franova J, Hlavackova E, Jancova E, Prochazkova L, Berankova K, et al. Muckle-Wells syndrome across four generations in one Czech family: Natural course of the disease. Frontiers in Immunology. 2019;10(MAR).
15.Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. New England Journal of Medicine. 2006;355(6):581-92.
16.Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008;58(8):2432-42.
17.Haas N, Kuster W, Zuberbier T, Henz BM. Muckle-Wells syndrome: Clinical and histological skin findings compatible with cold air urticaria in a large kindred. British Journal of Dermatology. 2004;151(1):99-104.
18.Hill SC, Namde M, Dwyer A, Poznanski A, Canna S, Goldbach-Mansky R. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol. 2007;37(2):145-52.
19.Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012;34(10):2091-103.
20.Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis and rheumatism. 2008;58(8):2443-52.
21.Hoffman HM, Wolfe F, Belomestnov P, Mellis SJ. Cryopyrin-associated periodic syndromes: Development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity. Current Medical Research and Opinion. 2008;24(9):2531-43.
22.Houx L, Hachulla E, Kone-Paut I, Quartier P, Touitou I, Guennoc X, et al. Musculoskeletal symptoms in patients with cryopyrin-associated periodic syndromes: A large database study. Arthritis and Rheumatology. 2015;67(11):3027-36.
23.Imagawa T, Nishikomori R, Takada H, Takeshita S, Patel N, Kim D, et al. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol. 2013;31(2):302-9.
24.Jaeger VK, Hoffman HM, van der Poll T, Tilson H, Seibert J, Speziale A, et al. Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. Rheumatology (Oxford). 2017;56(9):1484-91.
25.Jeyaratnam J, ter Haar NM, Lachmann HJ, Kasapcopur O, Ombrello AK, Rigante D, et al. The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: An international survey. Pediatric Rheumatology. 2018;16(1).
26.Johnstone RF, Dolen WK, Hoffman HM. A large kindred with familial cold autoinflammatory syndrome. Ann Allergy Asthma Immunol. 2003;90(2):233-7.

27.Kilic H, Sahin S, Duman C, Adrovic A, Barut K, Turanli ET, et al. Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome. European Journal of Paediatric Neurology. 2019;23(3):466-72.
28.Kitley JL, Lachmann HJ, Pinto A, Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology. 2010;74(16):1267-70.
29.Koitschev A, Gramlich K, Hansmann S, Benseler S, Plontke SK, Koitschev C, et al. Progressive familial hearing loss in Muckle-Wells syndrome. Acta Oto-Laryngologica. 2012;132(7):756-62.
30.Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis research & therapy. 2011;13(6).
31.Kone-Paut I, Quartier P, Fain O, Grateau G, Pillet P, Le Blay P, et al. Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study. Arthritis Care Res (Hoboken). 2017;69(6):903-11.
32.Kuemmerle-Deschner JB, Dembi Samba S, Tyrrell PN, Kone-Paut I, Marie I, Deschner N, et al. Challenges in diagnosing Muckle-Wells syndrome: identifying two distinct phenotypes. Arthritis Care Res (Hoboken). 2014;66(5):765-72.
33.Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095-102.
34.Kuemmerle-Deschner JB, Hofer F, Endres T, Kortus-Goetze B, Blank N, Weissbarth-Riedel E, et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology (Oxford). 2016;55(4):689-96.
35.Kuemmerle-Deschner JB, Koitschev A, Tyrrell PN, Plontke SK, Deschner N, Hansmann S, et al. Early detection of sensorineural hearing loss in Muckle-Wells-syndrome. Pediatric Rheumatology. 2015;13(1).
36.Kuemmerle-Deschner JB, Koitschev A, Ummenhofer K, Hansmann S, Plontke SK, Koitschev C, et al. Hearing loss in muckle-wells syndrome. Arthritis and Rheumatism. 2013;65(3):824-31.
37.Kuemmerle-Deschner JB, Lohse P, Koetter I, Dannecker GE, Reess F, Ummenhofer K, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment. Arthritis Research & Therapy. 2011:R196.
38.Kuemmerle-Deschner JB, Ramos E, Blank N, Roesler J, Felix SD, Jung T, et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther. 2011;13(1):R34.
39.Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, Wittkowski H, Bialkowski A, Tzaribachev N, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum. 2011;63(3):840-9.
40.Kuemmerle-Deschner JB, Verma D, Endres T, Broderick L, de Jesus AA, Hofer F, et al. Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges. Arthritis Rheumatol. 2017;69(11):2233-40.
41.Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, Koetter I, Lohse P, Ummenhofer K, et al. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther. 2013;15(3):R64.

42.Kullenberg T, Lofqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford). 2016;55(8):1499-506.
43.Kummerle-Deschner JB, Tyrrell PN, Reess F, Kotter I, Lohse P, Girschick H, et al. Risk factors for severe Muckle-Wells syndrome. Arthritis Rheum. 2010;62(12):3783-91.
44.Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416-25.
45.Lasiglie D, Mensa-Vilaro A, Ferrera D, Caorsi R, Penco F, Santamaria G, et al. Cryopyrin-associated periodic syndromes in Italian Patients: Evaluation of the rate of somatic NLRP3 mosaicism and phenotypic characterization. Journal of Rheumatology. 2017;44(11):1667-73.
46.Lauro CF, Goldbach-Mansky R, Schmidt M, Quezado ZMN. The anesthetic management of children with neonatal-onset multi-system inflammatory disease. Anesthesia and Analgesia. 2007;105(2):351-7.
47.Levy R, Gérard L, Kuemmerle-Deschner J, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis 2015;74(11):2043-9. doi: 10.1136/annrheumdis-2013-204991
48.Lepore L, Paloni G, Caorsi R, Alessio M, Rigante D, Ruperto N, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. Journal of Pediatrics. 2010;157(2):310-5.e1.
49.Li C, Tan X, Zhang J, Li S, Mo W, Han T, et al. Gene mutations and clinical phenotypes in 15 Chinese children with cryopyrin-associated periodic syndrome (CAPS). Science China. 2017;Life sciences. 60(12):1436-44.
50.Mamoudjy N, Maurey H, Marie I, Kone-Paut I, Deiva K. Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS). Orphanet J Rare Dis. 2017;12(1):33.
51.Mehr S, Allen R, Boros C, Adib N, Kakakios A, Turner PJ, et al. Cryopyrin-associated periodic syndrome in Australian children and adults: Epidemiological, clinical and treatment characteristics. Journal of Paediatrics and Child Health. 2016;52(9):889-95.
52.Miyamae T, Hanaya A, Kawamoto M, Tani Y, Kawaguchi Y, Yamanaka H. Diagnostic Rate of Autoinflammatory Diseases Evaluated by Fever Patterns in Pediatric- and Adult-Onset Patients. J Clin Rheumatol. 2020;26(2):60-2.
53.Mulders-Manders CM, Kanters TA, Van Daele PLA, Hoppenreijs E, Legger GE, Van Laar JAM, et al. Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: A questionnaire based cohort study. Orphanet Journal of Rare Diseases. 2018;13(1).
54.Nakagawa K, Gonzalez-Roca E, Souto A, Umebayashi H, Campistol JM, Canellas J, et al. Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. Annals of the Rheumatic Diseases. 2015;74(3):603-10.
55.Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis and Rheumatism. 2010;62(1):258-67.
56.Pastore S, Paloni G, Caorsi R, Ronfani L, Taddio A, Lepore L, et al. Serum amyloid protein A concentration in cryopyrin-associated periodic syndrome patients treated with interleukin-1 beta antagonist. Clinical and Experimental Rheumatology. 2014;32(Supplement84):S63-S6.

57.Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: A nationwide survey. Orphanet Journal of Rare Diseases. 2015;10(1).
58.Rowczenio DM, Gomes SM, Arostegui JI, Mensa-Vilaro A, Omoyinmi E, Trojer H, et al. Late-onset cryopyrin-associated periodic syndromes caused by somatic NLRP3 mosaicism-UK single center experience. Frontiers in Immunology. 2017;8(OCT).
59.Russo RA, Melo-Gomes S, Lachmann HJ, Wynne K, Rajput K, Eleftheriou D, et al. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. Rheumatology (Oxford). 2014;53(4):665-70.
60.Schuh E, Lohse P, Ertl-Wagner B, Witt M, Krumbholz M, Frankenberger M, et al. Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations. Neurology: Neuroimmunology and NeuroInflammation. 2015;2(4).
61.Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes. Arthritis and Rheumatism. 2012;64(7):2375-86.
62.Sobolewska B, Angermair E, Deuter C, Doycheva D, Kuemmerle-Deschner J, Zierhut M. NLRP3 A439V mutation in a large family with cryopyrin-associated periodic syndrome: Description of ophthalmologic symptoms in correlation with other organ symptoms. Journal of Rheumatology. 2016;43(6):1101-6.
63.Tanaka N, Izawa K, Saito MK, Sakuma M, Oshima K, Ohara O, et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: Results of an international multicenter collaborative study. Arthritis and Rheumatism. 2011;63(11):3625-32.
64.Turunen JA, Wedenoja J, Repo P, Jarvinen RS, Jantti JE, Mortenhumer S, et al. Keratoendotheliitis Fugax Hereditaria: A Novel Cryopyrin-Associated Periodic Syndrome Caused by a Mutation in the Nucleotide-Binding Domain, Leucine-Rich Repeat Family, Pyrin Domain-Containing 3 (NLRP3) Gene. American Journal of Ophthalmology. 2018;188:41-50.
65.Wiken M, Hallen B, Kullenberg T, Koskinen LO. Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study. Clinical Rheumatology. 2018;37(12):3381-6.
66.Wittkowski H, Kuemmerle-Deschner JB, Austermann J, Holzinger D, Goldbach-Mansky R, Gramlich K, et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Annals of the Rheumatic Diseases. 2011;70(12):2075-81.
67.Yokota S, Imagawa T, Nishikomori R, Takada H, Abrams K, Lheritier K, et al. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: Results from an open-label, phase III pivotal study in Japanese patients. Clinical and Experimental Rheumatology. 2017;35(Supplement108):S19-S26.

**II.2.** Included Articles for **TRAPS**

1.Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: A prospective, open-label, dose-escalation study. Arthritis Rheum 2012;64:908-13.
2.Cantarini L, Iacoponi F, Lucherini OM, Obici L, Brizi MG, Cimaz R, et al. Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults. International journal of immunopathology and pharmacology 2011;24:695-702.
3.Cantarini L, Lucherini OM, Cimaz R, Baldari CT, Bellisai F, Rossi Paccani S, et al. Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. International journal of immunopathology and pharmacology 2009;22:1051-8.
4.Cantarini L, Obici L, Simonini G, Cimaz R, Bacarelli MR, Merlini G, et al. Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (traps). Clin Exp Rheumatol 2012;30:S108-14.
5.Cantarini L, Rigante D, Merlini G, Vitale A, Caso F, Lucherini OM, et al. The expanding spectrum of low-penetrance tnfrsf1a gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up. Seminars in arthritis and rheumatism 2014;43:818-23.
6.De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 2018;378:1908-19.
7.Dingulu G, Georgin-Lavialle S, Koné-Paut I, Pillet P, Pagnier A, Merlin E, et al. Validation of the new classification criteria for hereditary recurrent fever in an independent cohort: Experience from the jir cohort database. Rheumatology (Oxford) 2020;59:2947-52.
8.Dodé C, André M, Bienvenu T, Hausfater P, Pêcheux C, Bienvenu J, et al. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002;46:2181-8.
9.D'Osualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, et al. Neutrophils from patients with tnfrsf1a mutations display resistance to tumor necrosis factor-induced apoptosis: Pathogenetic and clinical implications. Arthritis Rheum 2006;54:998-1008.
10.Federici L, Rittore-Domingo C, Koné-Paut I, Jorgensen C, Rodière M, Le Quellec A, et al. A decision tree for genetic diagnosis of hereditary periodic fever in unselected patients. Ann Rheum Dis 2006;65:1427-32.
11.Federici S, Sormani MP, Ozen S, Lachmann HJ, Amaryan G, Woo P, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 2015;74:799-805.
12.Federici S, Vanoni F, Ben-Chetrit E, Cantarini L, Frenkel J, Goldbach-Mansky R, et al. An international delphi survey for the definition of new classification criteria for familial mediterranean fever, mevalonate kinase deficiency, tnf receptor-associated periodic fever syndromes, and cryopyrin-associated periodic syndrome. The Journal of rheumatology 2019;46:429-36.
13.Gattorno M, Caorsi R, Meini A, Cattalini M, Federici S, Zulian F, et al. Differentiating pfapa syndrome from monogenic periodic fevers. Pediatrics 2009;124:e721-8.
14.Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 2019;78:1025-32.

15.Gattorno M, Obici L, Cattalini M, Tormey V, Abrams K, Davis N, et al. Canakinumab treatment for patients with active recurrent or chronic tnf receptor-associated periodic syndrome (traps): An open-label, phase ii study. Ann Rheum Dis 2017;76:173-8.
16.Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008;58:1516-20.
17.Hernández-Rodríguez J, Ruíz-Ortiz E, Tomé A, Espinosa G, González-Roca E, Mensa-Vilaró A, et al. Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. Autoimmun Rev 2016;15:9-15.
18.Hua Y, Wu D, Shen M, Yu K, Zhang W, Zeng X. Phenotypes and genotypes of chinese adult patients with systemic autoinflammatory diseases. Seminars in arthritis and rheumatism 2019;49:446-52.
19.Jesus AA, Fujihira E, Watase M, Terreri MT, Hilario MO, Carneiro-Sampaio M, et al. Hereditary autoinflammatory syndromes: A brazilian multicenter study. J Clin Immunol 2012;32:922-32.
20.Karagianni P, Nezos A, Ioakeim F, Tzioufas AG, Moutsopoulos HM. Analysis of nlrp3, mvk and tnfrsf1a variants in adult greek patients with autoinflammatory symptoms. Clin Exp Rheumatol 2018;36:86-9.
21.Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L, et al. The phenotype of tnf receptor-associated autoinflammatory syndrome (traps) at presentation: A series of 158 cases from the eurofever/eurotraps international registry. Ann Rheum Dis 2014;73:2160-7.
22.Lainka E, Neudorf U, Lohse P, Timmann C, Stojanov S, Huss K, et al. Incidence of tnfrsf1a mutations in german children: Epidemiological, clinical and genetic characteristics. Rheumatology (Oxford) 2009;48:987-91.
23.Lane T, Loeffler JM, Rowczenio DM, Gilbertson JA, Bybee A, Russell TL, et al. Aa amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 2013;65:1116-21.
24.Lucherini OM, Obici L, Ferracin M, Fulci V, McDermott MF, Merlini G, et al. First report of circulating micrornas in tumour necrosis factor receptor-associated periodic syndrome (traps). PLoS One 2013;8:e73443.
25.Lucherini OM, Vitale A, Obici L, Sota J, Frediani B, Merlini G, et al. Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (traps). Clin Exp Rheumatol 2019;37 Suppl 121:159-60.
26.McDermott EM, Smillie DM, Powell RJ. Clinical spectrum of familial hibernian fever: A 14-year follow-up study of the index case and extended family. Mayo Clinic proceedings 1997;72:806-17.
27.Nedjai B, Hitman GA, Quillinan N, Coughlan RJ, Church L, McDermott MF, et al. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2009;60:619-25.
28.Nevala H, Karenko L, Stjernberg S, Raatikainen M, Suomalainen H, Lagerstedt A, et al. A novel mutation in the third extracellular domain of the tumor necrosis factor receptor 1 in a finnish family with autosomal-dominant recurrent fever. Arthritis Rheum 2002;46:1061-6.
29.Obici L, Meini A, Cattalini M, Chicca S, Galliani M, Donadei S, et al. Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (traps) with or without aa amyloidosis. Ann Rheum Dis 2011;70:1511-2.

30.Ozen S, Kuemmerle-Deschner JB, Cimaz R, Livneh A, Quartier P, Kone-Paut I, et al. International retrospective chart review of treatment patterns in severe familial mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, and mevalonate kinase deficiency/hyperimmunoglobulinemia d syndrome. Arthritis Care Res (Hoboken) 2017;69:578-86.
31.Pelagatti MA, Meini A, Caorsi R, Cattalini M, Federici S, Zulian F, et al. Long-term clinical profile of children with the low-penetrance r92q mutation of the tnfrsf1a gene. Arthritis Rheum 2011;63:1141-50.
32.Piram M, Frenkel J, Gattorno M, Ozen S, Lachmann HJ, Goldbach-Mansky R, et al. A preliminary score for the assessment of disease activity in hereditary recurrent fevers: Results from the aidai (auto-inflammatory diseases activity index) consensus conference. Ann Rheum Dis 2011;70:309-14.
33.Piram M, Koné-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, et al. Validation of the auto-inflammatory diseases activity index (aidai) for hereditary recurrent fever syndromes. Ann Rheum Dis 2014;73:2168-73.
34.Quillinan N, Mannion G, Mohammad A, Coughlan R, Dickie LJ, McDermott MF, et al. Failure of sustained response to etanercept and refractoriness to anakinra in patients with t50m tnf-receptor-associated periodic syndrome. Ann Rheum Dis 2011;70:1692-3.
35.Quillinan N, Mohammad A, Mannion G, O'Keeffe D, Bergin D, Coughlan R, et al. Imaging evidence for persistent subclinical fasciitis and arthritis in tumour necrosis factor receptor-associated periodic syndrome (traps) between febrile attacks. Ann Rheum Dis 2010;69:1408-9.
36.Ravet N, Rouaghe S, Dodé C, Bienvenu J, Stirnemann J, Lévy P, et al. Clinical significance of p46l and r92q substitutions in the tumour necrosis factor superfamily 1a gene. Ann Rheum Dis 2006;65:1158-62.
37.Ruiz-Ortiz E, Iglesias E, Soriano A, Buján-Rivas S, Español-Rego M, Castellanos-Moreira R, et al. Disease phenotype and outcome depending on the age at disease onset in patients carrying the r92q low-penetrance variant in tnfrsf1a gene. Frontiers in immunology 2017;8:299.
38.Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, et al. Treatment of autoinflammatory diseases: Results from the eurofever registry and a literature review. Ann Rheum Dis 2013;72:678-85.
39.Ter Haar NM, Annink KV, Al-Mayouf SM, Amaryan G, Anton J, Barron KS, et al. Development of the autoinflammatory disease damage index (addi). Ann Rheum Dis 2017;76:821-30.
40.ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015;74:1636-44.
41.Ter Haar NM, van Delft ALJ, Annink KV, van Stel H, Al-Mayouf SM, Amaryan G, et al. In silico validation of the autoinflammatory disease damage index. Ann Rheum Dis 2018;77:1599-605.
42.Torene R, Nirmala N, Obici L, Cattalini M, Tormey V, Caorsi R, et al. Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis 2017;76:303-9.
43.Toro JR, Aksentijevich I, Hull K, Dean J, Kastner DL. Tumor necrosis factor receptor-associated periodic syndrome: A novel syndrome with cutaneous manifestations. Arch Dermatol 2000;136:1487-94.

44.Ueda N, Ida H, Washio M, Miyahara H, Tokunaga S, Tanaka F, et al. Clinical and genetic features of patients with tnfrsf1a variants in japan: Findings of a nationwide survey. Arthritis Rheumatol 2016;68:2760-71.
45.Vergara C, Borzutzky A, Gutierrez MA, Iacobelli S, Talesnik E, Martinez ME, et al. Clinical and genetic features of hereditary periodic fever syndromes in hispanic patients: The chilean experience. Clinical rheumatology 2012;31:829-34.
46.Weyhreter H, Schwartz M, Kristensen TD, Valerius NH, Paerregaard A. A new mutation causing autosomal dominant periodic fever syndrome in a danish family. The Journal of pediatrics 2003;142:191-3.
47.Williamson LM, Hull D, Mehta R, Reeves WG, Robinson BH, Toghill PJ. Familial hibernian fever. The Quarterly journal of medicine 1982;51:469-80.

**II.3.** Included Articles for **MKD**

1.Haraldsson A, Weemaes CMR, De Boer AW, Bakkeren JAJM, Stoelinga GBA. Immunological studies in the hyper-immunoglobulin D syndrome. Journal of Clinical Immunology. 1992;12(6):424-8.
2.Loeliger AE, Kruize AA, Bijilsma JW, Loeliger AE, Derksen RH. Arthritis in hyperimmunoglobulinaemia D. Ann Rheum Dis. 1993;52(1):81.
3.Drenth JP, Boom BW, Toonstra J, Van der Meer JW. Cutaneous manifestations and histologic findings in the hyperimmunoglobulinemia D syndrome. International Hyper IgD Study Group. Arch Dermatol. 1994;130(1):59-65.
4.Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore). 1994;73(3):133-44.
5.Drenth JP, Mariman EC, Van der Velde-Visser SD, Ropers HH, Van der Meer JW. Location of the gene causing hyperimmunoglobulinemia D and periodic fever syndrome differs from that for familial Mediterranean fever. International Hyper-IgD Study Group. Hum Genet. 1994;94(6):616-20.
6.Drenth JP, Powell RJ, Brown NS, Van der Meer JW. Interferon-gamma and urine neopterin in attacks of the hyperimmunoglobulinaemia D and periodic fever syndrome. Eur J Clin Invest. 1995;25(9):683-6.
7.Livneh A, Drenth JPH, Klasen IS, Langevitz P, George J, Shelton DA, et al. Familial Mediterranean fever and hyperimmunoglobulinemia D syndrome: Two diseases with distinct clinical, serologic, and genetic features. Journal of Rheumatology. 1997;24(8):1558-63.
8.Houten SM, Kuis W, Duran M, de Koning TJ, van Royen-Kerkhof A, Romeijn GJ, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet. 1999;22(2):175-7.
9.Poll-The BT, Frenkel J, Houten SM, Kuis W, Duran M, De Koning TJ, et al. Mevalonic aciduria in 12 unrelated patients with hygerimmunoglobulinaemia D and periodic fever syndrome. Journal of Inherited Metabolic Disease. 2000;23(4):363-6.
10.de Dios Garcia-Diaz J, Alvarez-Blanco MJ. High IgD could be a nonpathogenetic diagnostic marker of the hyper-IgD and periodic fever syndrome. Ann Allergy Asthma Immunol. 2001;86(5):587.
11.Drenth JP, Vonk AG, Simon A, Powell R, van der Meer JW. Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. J Pharmacol Exp Ther. 2001;298(3):1221-6.
12.Frenkel J, Houten SM, Waterham HR, Wanders RJA, Rijkers GT, Duran M, et al. Clinical and molecular variability in childhood periodic fever with hyperimmunoglobulinaemia D. Rheumatology. 2001;40(5):579-84.
13.Simon A, Cuisset L, Vincent MF, Van der Velde-Visser SD, Delpech M, Van der Meer JWM, et al. Molecular analysis of the mevalonate kinase gene in a cohort of patients with the hyper-IgD and periodic fever syndrome: Its application as a diagnostic tool. Annals of Internal Medicine. 2001;135(5):338-43.
14.Simon A, Bijzet J, Voorbij HAM, Mantovani A, Van Der Meer JWM, Drenth JPH. Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. Journal of Internal Medicine. 2004;256(3):247-53.

15.Simon A, Drewe E, van der Meer JW, Powell RJ, Kelley RI, Stalenhoef AF, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther. 2004;75(5):476-83.
16.Simon A, Kremer HP, Wevers RA, Scheffer H, De Jong JG, Van Der Meer JW, et al. Mevalonate kinase deficiency: Evidence for a phenotypic continuum. Neurology. 2004;62(6):994-7.
17.Stojanov S, Lohse P, Lohse P, Hoffmann F, Renner ED, Zellerer S, et al. Molecular analysis of the MVK and TNFRSF1A genes in patients with a clinical presentation typical of the hyperimmunoglobulinemia D with periodic fever syndrome: a low-penetrance TNFRSF1A variant in a heterozygous MVK carrier possibly influences the phenotype of hyperimmunoglobulinemia D with periodic fever syndrome or vice versa. Arthritis Rheum. 2004;50(6):1951-8.
18.D'Osualdo A, Picco P, Caroli F, Gattorno M, Giacchino R, Fortini P, et al. MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever. Eur J Hum Genet. 2005;13(3):314-20.
19.Federici L, Rittore-Domingo C, Kone-Paut I, Jorgensen C, Rodiere M, Le Quellec A, et al. A decision tree for genetic diagnosis of hereditary periodic fever in unselected patients. Annals of the Rheumatic Diseases. 2006;65(11):1427-32.
20.Oretti C, Barbi E, Marchetti F, Lepore L, Ventura A, D'Osualdo A, et al. Diagnostic challenge of hyper-IgD syndrome in four children with inflammatory gastrointestinal complaints. Scand J Gastroenterol. 2006;41(4):430-6.
21.Ammouri W, Cuisset L, Rouaghe S, Rolland MO, Delpech M, Grateau G, et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology (Oxford). 2007;46(10):1597-600.
22.Bodar EJ, van der Hilst JC, van Heerde W, van der Meer JW, Drenth JP, Simon A. Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood. 2007;109(6):2416-8.
23.Van Der Hilst JCH, Bodar EJ, Barron KS, Frenkel J, Drenth JPH, Van Der Meer JWM, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine. 2008;87(6):301-10.
24.Gattorno M, Caorsi R, Meini A, Cattalini M, Federici S, Zulian F, et al. Differentiating PFAPA syndrome from monogenic periodic fevers. Pediatrics. 2009;124(4):e721-8.
25.Steichen O, van der Hilst J, Simon A, Cuisset L, Grateau G. A clinical criterion to exclude the hyperimmunoglobulin D syndrome (mild mevalonate kinase deficiency) in patients with recurrent fever. J Rheumatol. 2009;36(8):1677-81.
26.Bader-Meunier B, Florkin B, Sibilia J, Acquaviva C, Hachulla E, Grateau G, et al. Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics. 2011;128(1):e152-9.
27.Bodar EJ, Kuijk LM, Drenth JPH, Van Der Meer JWM, Simon A, Frenkel J. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Annals of the Rheumatic Diseases. 2011;70(12):2155-8.
28.Galeotti C, Meinzer U, Quartier P, Rossi-Semerano L, Bader-Meunier B, Pillet P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford). 2012;51(10):1855-9.
29.Jesus AA, Fujihira E, Watase M, Terreri MT, Hilario MO, Carneiro-Sampaio M, et al. Hereditary autoinflammatory syndromes: a Brazilian multicenter study. J Clin Immunol. 2012;32(5):922-32.

30.Lainka E, Neudorf U, Lohse P, Timmann C, Bielak M, Stojanov S, et al. Incidence and clinical features of hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) and spectrum of mevalonate kinase (MVK) mutations in German children. Rheumatol Int. 2012;32(10):3253-60.
31.Tas DA, Dinkci S, Erken E. Different clinical presentation of the hyperimmunoglobulin D syndrome (HIDS) (four cases from Turkey). Clin Rheumatol. 2012;31(5):889-93.
32.Haar NT, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C, et al. Treatment of autoinflammatory diseases: Results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases. 2013;72(5):678-85.
33.Lane T, Loeffler JM, Rowczenio DM, Gilbertson JA, Bybee A, Russell TL, et al. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis and Rheumatism. 2013;65(4):1116-21.
34.Stabile A, Compagnone A, Napodano S, Raffaele CG, Patti M, Rigante D. Mevalonate kinase genotype in children with recurrent fevers and high serum IgD level. Rheumatol Int. 2013;33(12):3039-42.
35.Piram M, Kone-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73(12):2168-73.
36.Berody S, Galeotti C, Kone-Paut I, Piram M. A restrospective survey of patients's journey before the diagnosis of mevalonate kinase deficiency. Joint Bone Spine. 2015;82(4):240-4.
37.De Pieri C, Taddio A, Insalaco A, Barbi E, Lepore L, Ventura A, et al. Different presentations of mevalonate kinase deficiency: A case series. Clinical and Experimental Rheumatology. 2015;33(3):437-42.
38.Van Der Hilst JCH, Drenth JPH, Bodar EJ, Bijzet J, Van Der Meer JWM, Simon A. Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome. Amyloid. 2005;12(2):115-119.
39.Durel CA, Aouba A, Bienvenu B, Deshayes S, Coppere B, Gombert B, et al. Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency. Medicine (Baltimore). 2016;95(11):e3027.
40.Jeyaratnam J, Ter Haar NM, de Sain-van der Velden MG, Waterham HR, van Gijn ME, Frenkel J. Diagnostic Value of Urinary Mevalonic Acid Excretion in Patients with a Clinical Suspicion of Mevalonate Kinase Deficiency (MKD). JIMD Rep. 2016;27:33-8.
41.ter Haar NM, Jeyaratnam J, Lachmann HJ, Simon A, Brogan PA, Doglio M, et al. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology. 2016;68(11):2795-805.
42.Arostegui JI, Anton J, Calvo I, Robles A, Iglesias E, Lopez-Montesinos B, et al. Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome. Arthritis Rheumatol. 2017;69(8):1679-88.
43.Ozen S, Kuemmerle-Deschner JB, Cimaz R, Livneh A, Quartier P, Kone-Paut I, et al. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care and Research. 2017;69(4):578-86.
44.Papa R, Doglio M, Lachmann HJ, Ozen S, Frenkel J, Simon A, et al. A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet Journal of Rare Diseases. 2017;12(1).

45.De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018;378(20):1908-19.
46.Deshayes S, Georgin-Lavialle S, Hot A, Durel CA, Hachulla E, Rouanes N, et al. Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. J Rheumatol. 2018;45(3):425-9.
47.Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, et al. Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases. 2019.
48.Munoz MA, Jurczyluk J, Simon A, Hissaria P, Arts RJW, Coman D, et al. Defective Protein Prenylation in a Spectrum of Patients With Mevalonate Kinase Deficiency. Front Immunol. 2019;10:1900.
49.Tanaka T, Yoshioka K, Nishikomori R, Sakai H, Abe J, Yamashita Y, et al. National survey of Japanese patients with mevalonate kinase deficiency reveals distinctive genetic and clinical characteristics. Mod Rheumatol. 2019;29(1):181-7.
50.Al-Mayouf SM, Almutairi A, Albrawi S, Fathalla BM, Alzyoud R, AlEnazi A, et al. Pattern and diagnostic evaluation of systemic autoinflammatory diseases other than familial Mediterranean fever among Arab children: a multicenter study from the Pediatric Rheumatology Arab Group (PRAG). Rheumatol Int. 2020;40(1):49-56.
51.Conte M, Pastore S, Berti I, Taddio A, Tommasini A. Cutaneous manifestations in mevalonate kinase deficient patients treated with canakinumab. Clin Exp Rheumatol. 2020.

**II.4.** Included Articles for **DIRA**

1.Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360(23):2426–37.
2. Garg M, de Jesus AA, Chapelle D, Dancey P, Herzog R, Rivas-Chacon R, Wampler Muskardin TL, Reed A, Benvin S, Mellis S, Goldbach-Mansky R, Montealegre Sanchez GA. (2017). Rilonacept in patients with Deficiency of the IL-1 receptor antagonist (DIRA) maintains long-term inflammatory remission. JCI Insight. 2017 Aug 17;2(16). PMID: 28814674

## II.5. Statements that cannot reached consensus

### 1. CAPS

**1**. In patients with clinical features of autoinflammatory disease and blood parameters of systemic inflammation in the absence of infection are the following clinical features listed below highly likely to suggest CAPS, compared with patients lacking these characteristics?

- visual loss (57%)

**2.** In patients with clinical features of autoinflammatory disease suggestive of CAPS are there features listed below that can differentiate patients within the CAPS spectrum compared with patients lacking these characteristics in order to define such patients as having mild, moderate or severe disease?

- visual loss (64%)

**3.** In patients with presumed CAPS can we use similar diagnostic tests listed below compared to non-CAPS patients to more definitively make a diagnosis on the CAPS spectrum?

- Measurement of markers of inflammasome activation such as IL-1 release in whole blood assays, ASC speck may be helpful (64%)
- MRI (77%)
- Spinal tap (54%)
- Bone film or MRI for suspected bone damage (46%)

**6.** For patients with CAPS symptoms, are certain lab markers listed below, compared to healthy donors, helpful in the diagnosis of CAPS

- Cytokine panels (46%)

**7.** For patients with CAPS is additional diagnostic workup including studies listed below, compared to serologic labs only, useful in the diagnosis of CAPS

- In vitro secretion of IL-1 by monocytes (or ASC) in patients with variants of unknown origin (61.1%)

**19.** What are the recommendations for pneumococcal vaccination in CAPS patients?

- Pneumococcal polysaccharide (No:86%)

**22.** Should disease activity and damage be monitored in CAPS patients using the following methods, and does this differ along the clinical CAPS spectrum?

- Tissue biopsy for amyloidosis (31%)
- Muckle Wells activity score (54%)
- CNS MRI (including inner ear) (69%)

**23.** Which of the following tests listed below should be included in yearly monitoring of CAPS patients along the CAPS spectrum

- Head MRI (75%)

## 2. TRAPS

**7.** In patients with a suspected TRAPS, which additional examination in respect to acute phase reactants, would be useful to complete the diagnostic work-up?

- Abdominal fat pad aspirates evaluated by polarizing microscopy of Congo Red stained sections in patients with suspected SAA amyloidosis (78.3%)

**9.** When checking a patient with recurrent fever, which other conditions should be taken into account as differential diagnosis with TRAPS?

- PFAPA (periodic fever, aphthous stomatitis, pharyngitis, adenitis) syndrome (70%)

**12.** Apart from IL-1 blockade, does the following drugs have a beneficial efficacy/safety ratio (trade-off) for improving symptoms for TRAPS compared to no treatment?

- Anti-TNF monoclonal antibody (33.3%)
- Anti-IL6 (63.2%)

## 3. MKD

**5.** Are the following drugs effective for the treatment of MKD, compared to no treatment?

- Anti IL-6 (55%)

## 4. DIRA

**1.** In patients with presumed DIRA can a similar diagnostic approach compared to patients who do not have a suspicion of an IL-1 mediated disease be used to make the diagnosis of DIRA?

- Blood and functional measures of organ damage (42.9%)

**2**. For patients with DIRA symptoms, is additional diagnostic workup such as bone scan and MRI/CT to assess odontoid compared to serologic labs only useful in the diagnosis DIRA?

- Bone scan for all patients regardless of the severity of disease (33%)

**3.** Is a firm genetic diagnosis always required before treatment can be started?

- Genetic diagnosis is required (22.2%)

## II.6. Dropped statements

### 1. CAPS

**2.** In patients with clinical features of autoinflammatory disease suggestive of CAPS are there features listed below that can differentiate patients within the CAPS spectrum compared with patients lacking these characteristics in order to define such patients as having mild, moderate or severe disease?

- Urticaria-like rash (No: 86%)

**3.** In patients with presumed CAPS can we use similar diagnostic tests listed below compared to non-CAPS patients to more definitively make a diagnosis on the CAPS spectrum?

- Blood and functional measures of organ damage (No:100%)

**12.** In patients with CAPS, which of the therapies from the list below compared to no therapy have been shown to reduce flares and long-term complications

- Corticosteroids (No: 100%)

**22.** Should disease activity and damage be monitored in CAPS patients using the following methods, and does this differ along the clinical CAPS spectrum?

- Nuclear medicine scanning for amyloidosis (No:92%)

### 2. TRAPS

**1.** Skin biopsy is useful for the diagnosis of TRAPS (No:90%)

**10.** In patients with a suspected TRAPS, the presence of a positive genetic test, in respect to other autoinflammatory diseases, is always mandatory before treatment can be started? (No: 87.5%)

**12.** Apart from IL-1 blockade, does the following drugs have a beneficial efficacy/safety ratio (trade-off) for improving symptoms for TRAPS compared to no treatment?

- Colchicine (83.3%)

### 3. MKD

**5.** Are the following drugs effective for the treatment of MVKD, compared to no treatment?

- DMARDs (No: 94.7%)
- Colchicine (No: 82 %)

### 4. DIRA

**5.** In patients with DIRA, which of the therapies from the list below compared to no therapy have been shown to reduce flares and long-term complications

- Corticosteroids (No:92.9%)

- NSAIDs (No:97.5 %)

**14.** In patients with DIRA, is every other day therapy with anakinra compared to daily therapy sufficient to reduce flares and long-term complications in DIRA? (46.2%)

**21.** How should disease activity and damage be monitored? Does this differ along the clinical spectrum?

- PASI (100%)
- Other Psoriasis QoL measures (100%)
- CHAQ 100% (decided during the discussion)

## REFERENCES

1. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. *Ann Rheum Dis* 2015;74(1):8-13. doi: 10.1136/annrheumdis-2014-206350 [published Online First: 2014/09/28]